Skip to main content

Vaccine effectiveness of BNT162b2 against Delta and Omicron variants in adolescents

Buchan SA, Nguyen L, Wilson SE, Kitchen SA, Kwong JC. Pediatrics. 2022; Jun 16 [Epub ahead of print]. DOI: https://doi.org/10.1542/peds.2022-057634


There are limited data on vaccine effectiveness (VE) against the Omicron variant in adolescents. In Ontario, Canada, most vaccinated adolescents completed their primary series of BNT162b2 during summer 2021; third dose eligibility (6 months following a second dose) expanded to those aged 12-17 years in February 2022. We estimated 2-dose and 3-dose VE against Omicron (BA.1/BA.1.1) and Delta for this age group.

View full text

×